Effect of Pemafibrate on Liver Function in Type 2 Diabetes With Hypertriglyceridemia

Abstract

Pemafibrate, a selective peroxisome proliferator activated receptor α modulator (SPPARMα), reduces blood triglyceride levels. In addition, it was reported that pemafibrate improved the liver function and liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). In 32 type 2 diabetes patients with hypertriglycemia who received pemafibrate (0.1 mg) twice a day for 1 year, the levels of serum triglyceride, AST, ALT, and γ-GTP decreased after one year compared with the baseline. In 14 NAFLD patients, the serum ALT level significantly decreased after 1 year. The change in the serum ALT level significantly correlated with the HbA1c value, serum AST level, and serum ALT level before pemafibrate dosage. In type 2 diabetes patients with hypertriglycemia, pemafibrate improved hypertriglycemia, and in NAFLD patients, pemafibrate improved the liver function one year later.